期刊文献+

复发难治性恶性B细胞肿瘤患者行嵌合抗原受体T细胞免疫治疗的护理 被引量:7

Nursing care of patients with recurrent refractory malignant B cell tumor after chimeric antigen receptor T cell immunotherapy
下载PDF
导出
摘要 目的总结15例嵌合抗原受体T细胞免疫疗法治疗复发难治性恶性B细胞血液肿瘤患者的护理经验。方法对15例复发难治性恶性B细胞血液肿瘤患者行嵌合抗原受体T细胞免疫疗法治疗,同时实施预处理及细胞回输阶段的准备和护理,密切观察细胞因子释放综合征、凝血功能异常、神经系统毒性等不良反应,加强医护合作并正确执行医嘱,关注患者的癌症复发恐惧心理,重视心理护理。结果14例患者治疗后好转出院,1例CRS 4级患者因多器官功能衰竭,出院后疾病进展性死亡。结论规范的护理有利于减轻患者的痛苦,保证治疗顺利进行。
作者 袁淑蕾 杨英 李维 胡丽丽 方云 Yuan Shulei;Yang Ying;Li Wei;Hu Lili;Fang Yun
出处 《护理学杂志》 CSCD 北大核心 2020年第6期33-35,共3页 Journal of Nursing Science
  • 相关文献

参考文献7

二级参考文献23

  • 1Yan CH, Wang JZ, Liu DH, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoetic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors[J]. Eur J Haematol, 2013, 91(4) :304- 314. DOh 10. llll/ejh. 12168.
  • 2Kolb HJ, Schattenherg A, Goldman JM, et al. Graft-versus- leukemia effect of donor lymphocyte transfusions in marrow grafted patients[J]. Blood, 1995, 86(5) :2041-2050.
  • 3Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer[J]. J Clin Invest, 2015, 125(9) :3335- 3337. DOI: 10. 1172/JCI83871.
  • 4Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastie leukemia (ALL) 'J]. Ther Adv Hematol, 2015, 6 (5) : 228-41. DOh 10. 1177/2040620715588916.
  • 5Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. NEngl J Med, 2014, 371 (16): 1507-1517. DOI: 10. 1056/ NEJMoa1407222.
  • 6Brudno JN, Somerville RP, Shi V, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allngeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease[J]. J Clin Oncol, 2016, 34(10):1112-1121. DOI: 10. 1200/JCO. 2015.64. 5929.
  • 7Zhao XS, YanCH, LiuDH, etal. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity[J]. Ann Hematol, 2013, 92(8):1111-1119. DOI: 10. 1007/s00277-013-1733-1.
  • 8Spyridonidis A, Labopin M, Schmicl C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT[J]. Leukemia, 2012, 26 (6): 1211-1217. DOI: 10. 1038/leu. 2011.351.
  • 9Cameron T, Carolina B, Daniel S, et al. Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non- Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes[J]. Blood, 2015, 126(23): 184.
  • 10Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia [J].Sci Transl Med. 2015, 7 (303): 303ra139. DOI: 10. 1126/ scitranslmed, aac5415.

共引文献85

同被引文献95

引证文献7

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部